Balanced Intersystem Crossing in Iodinated Silicon-Fluoresceins Allows New Class of Red Shifted Theranostic Agents.


Creative Commons License

Cetin S., Elmazoglu Z., Karaman O., Gunduz H., Günbaş E. G., Kolemen S.

ACS medicinal chemistry letters, vol.12, pp.752-757, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12
  • Publication Date: 2021
  • Doi Number: 10.1021/acsmedchemlett.1c00018
  • Journal Name: ACS medicinal chemistry letters
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, BIOSIS, Chemical Abstracts Core, EMBASE
  • Page Numbers: pp.752-757
  • Keywords: Photodynamic therapy, cancer, theranostic, silicon-fluorescein, fluorescence imaging, SINGLET OXYGEN GENERATION, SUBSTITUTED XANTHENE DYES, PHOTODYNAMIC THERAPY, BODIPY DYES, CANCER, PHOTOSENSITIZERS, PROBES
  • Middle East Technical University Affiliated: Yes

Abstract

© 2021 The Authors. Published by American Chemical Society.Iodination of the silicon-fluorescein core revealed a new class of highly cytotoxic, red-shifted and water-soluble photosensitizer (SF-I) which is also fairly emissive to serve as a theranostic agent. Singlet oxygen generation capacity of SF-I was evaluated chemically, and up to 45% singlet oxygen quantum yield was reported in aqueous solutions. SF-I was further tested in triple negative breast (MDA MB-231) and colon (HCT-116) cancer cell lines, which are known to have limited chemotherapy options as well as very poor prognosis. SF-I induced efficient singlet oxygen generation and consequent photocytotoxicity in both cell lines upon light irradiation with a negligible dark toxicity while allowing cell imaging at the same time. SF-I marks the first ever example of a silicon xanthene-based photosensitizer and holds a lot of promise as a small-molecule-based theranostic scaffold.